U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07353671) titled 'Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis' on Dec. 14, 2025.
Brief Summary: To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.
Study Start Date: Feb. 01
Study Type: INTERVENTIONAL
Condition:
Radiation-induced Dermatitis
Intervention:
DRUG: Topical application of Periplaneta americana-derived Meilian Fuxin Solution
A topical formulation derived from Periplaneta americana (Meilian Fuxin Solution).
OTHER: Topical application of placebo
The placebo topical for...